IGF-1 levels and aging — what the data shows
IGF-1 declines with age, but the relationship to health outcomes is U-shaped. What the data actually shows — and how to read your own number.
May 7, 2026 · 7 min read · By Strength Peptide Editors
IGF-1 levels and aging is one of those topics where the literature is reasonably mature, the headlines are often wrong, and the practical takeaway for an individual is more nuanced than "low is bad" or "high is good." This post walks through what the data actually shows about IGF-1 across the adult lifespan, why the longevity story is U-shaped rather than linear, and how to read your own number against age-adjusted ranges if you're considering GH peptides.
What IGF-1 is, briefly
IGF-1 (insulin-like growth factor 1) is a hormone produced mostly by the liver in response to growth hormone signaling. Where GH is pulsatile and short-lived in blood, IGF-1 is stable across the day. That stability is what makes it the practical lab marker for the GH axis — a single morning draw integrates a few days of GH activity.
IGF-1 mediates a lot of what GH does in tissue: protein synthesis, cell proliferation, collagen turnover, glucose handling, and a long list of growth-related processes. It's also a known modulator of cancer biology, which is the source of the more cautious literature.
The age curve
IGF-1 follows a recognizable shape across the lifespan:
| Life stage | Typical IGF-1 trajectory |
|---|---|
| Childhood | Rising slowly |
| Puberty | Sharp spike — peaks in mid-to-late teens |
| 20s | High, slowly declining from the teen peak |
| 30s | Continued slow decline |
| 40s | Decline becomes more visible |
| 50s | Lower-mid range typical |
| 60s+ | Lower range typical; some users near floor of normal |
The decline through adulthood roughly tracks the GH-axis decline described in the broader GH-axis aging literature. It's gradual, with wide individual variation, and modulated by sleep, body composition, exercise, sex steroids, and chronic disease.
A practical implication: the lab reference range you see on a result is age-adjusted. A 50-year-old whose IGF-1 lands at 150 ng/mL might be flagged as normal for age; a 25-year-old at the same number is well below age-adjusted range. The reference range is doing a lot of work, and it's specific to your decade.
The U-shape: low is bad, high is bad
This is the part the popular discussion usually misses.
If you plot IGF-1 against all-cause mortality or longevity-related outcomes in observational cohorts, the relationship isn't linear. It's roughly U-shaped — both ends of the distribution carry elevated risk, for different reasons:
- Very low IGF-1 is associated with worse outcomes related to frailty, sarcopenia, cardiovascular events, and malnutrition. Low IGF-1 is a marker of upstream problems in a lot of older adults.
- Very high IGF-1 is associated with elevated risk for certain cancers — most consistently breast, prostate, and colorectal — and possibly with insulin-resistance-linked cardiovascular outcomes.
- The mid-to-upper-normal range tends to look best across multiple outcomes.
The U-shape is consistent enough across cohorts to be worth taking seriously. It does not say "IGF-1 is bad." It says the relationship between IGF-1 and aging biology is dose-shaped, not monotonic.
Why the cancer signal exists
IGF-1 is, mechanistically, a growth signal. It promotes cell survival, suppresses apoptosis in some contexts, and supports proliferation. Cancer biology overlaps with these functions: tumor cells often hijack the IGF-1 axis. The epidemiologic signal — higher endogenous IGF-1 associated with higher risk of certain cancers — is consistent with this mechanism, though it's not a settled causal claim and effect sizes are modest.
What this matters for in practice:
- People with a personal or family history of hormone-sensitive cancers should approach intentional IGF-1 elevation with extra caution.
- Elevating IGF-1 above age-adjusted normal with secretagogues or other interventions probably shouldn't be the goal. Restoring it to mid-to-upper-normal is a more defensible target.
- Continuous high-dose protocols carry more theoretical risk than intermittent moderate-dose protocols.
The deeper treatment lives in IGF-1 LR3 cancer concerns and peptides and cancer history.
The "low IGF-1 in centenarians" wrinkle
Some longevity research famously points to low IGF-1 signaling as a marker of exceptional lifespan — Laron syndrome, certain centenarian cohorts, and various model organisms with reduced IGF-1 signaling living longer. This is real, and it complicates the picture.
The reconciliation most researchers offer: very low lifelong IGF-1 signaling, often genetic, is distinct from acquired low IGF-1 in middle age driven by other problems. The first is a developmental/genetic profile that confers some resistance to age-related disease. The second is often a marker of those problems already present. Both can be associated with longevity in different ways.
For a middle-aged person looking at their own number, this means: a low IGF-1 in your 50s is not "the centenarian phenotype." It's more often a sign of something correctable upstream.
How to read your own IGF-1
A workable interpretation framework:
| Result | What it usually means |
|---|---|
| Below age range | Investigate. Look at sleep, body comp, thyroid, liver, nutrition, chronic disease. |
| Lower-mid age range | Common in middle age. Often a target for GH-peptide users to nudge up. |
| Mid-to-upper age range | The sweet spot most users aim for. |
| Above age range | Re-check. If sustained, dial back any peptide protocol. |
| Well above age range | Stop and re-evaluate. Consider acromegaly workup if persistent without exogenous cause. |
Two important asterisks. First, lab-to-lab IGF-1 ranges differ — read the reference range that came with your specific result. Second, IGF-1 has substantial day-to-day variability driven by acute illness, hard training, and crash diets. One result is one data point; trends matter more than single readings.
What moves IGF-1 (without peptides)
The non-pharmacologic levers are real and underrated:
- Sleep. The largest natural GH pulse is in deep sleep. Restoring sleep architecture often nudges IGF-1.
- Resistance training. Chronic strength training is associated with modestly higher IGF-1.
- Adequate protein. Severe protein restriction lowers IGF-1; adequate protein supports it.
- Body composition. Lower visceral fat is associated with better GH pulsatility and IGF-1.
- Treating thyroid disease. Hypothyroidism can blunt IGF-1.
Before reaching for a secretagogue, the question is whether the upstream levers are pulled. A user with five hours of poor sleep and central adiposity will get more IGF-1 movement from fixing those than from any peptide protocol.
What GH peptides do to IGF-1
For users running secretagogues, IGF-1 typically responds in a recognizable pattern:
- Sermorelin alone: modest IGF-1 elevation, often 10–30% above baseline at 8–12 weeks
- Ipamorelin + CJC-1295 (no DAC): more pronounced elevation, depending on dose and frequency
- CJC-1295 with DAC: larger elevation, but flatter — the pulsatile signal is partly lost
- Tesamorelin: among the strongest secretagogue elevations, with the strongest clinical record
- MK-677: substantial elevation, with the side-effect tradeoffs of the compound
Numbers vary widely between users. For most middle-aged secretagogue users, the goal is moving from lower-mid into mid-to-upper-normal for age — not pushing into supraphysiologic territory.
The practical posture
A defensible read of the IGF-1-and-aging data:
- IGF-1 declines with age. That decline is normal, but it isn't always optimal.
- Both low and high IGF-1 are associated with worse outcomes. Aim for the middle.
- Mid-to-upper age-adjusted normal is a reasonable target. Above age range is not.
- Track over time. Single readings are noisy; trends are meaningful.
- Rule out upstream causes of low IGF-1 before assuming GH peptides are the answer.
- Cancer-axis caution applies — especially for users with family or personal history.
The IGF-1 number on your lab result is informative, but it isn't a verdict. It's a snapshot of one node in a long-running system. Read it that way.
Related reading
Free weekly newsletter
Get the strength peptide highlights, weekly.
One short email a week — new guides, study readouts, supply updates, and dosing tips. Plain-English, no spam.
Unsubscribe anytime. We never share your email.